Barry Ticho - 17 Mar 2026 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Reporting relationship: CHIEF MEDICAL OFFICER
Issuer ticker: STOK
Reported as of: 17 Mar 2026
Net transaction value: -$456,835
SEC form: 4
Accepted by SEC: 19 Mar 2026, 18:01:54 UTC
Prior SEC filing: 17 Mar 2026
Next SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Jonathan Allan, Attorney-in-Fact

Key filing fact

Barry Ticho filed Form 4 for Stoke Therapeutics, Inc. (STOK) on 19 Mar 2026.

Key facts

This page summarizes Barry Ticho's Form 4 filing for Stoke Therapeutics, Inc. (STOK).
8 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Mar 2026, 18:01.

Change

Previous filing in this sequence was filed on 17 Mar 2026.
Current net transaction value: -$456,835.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001780088 Primary reporting owner

Ticho Barry

Relationship: CHIEF MEDICAL OFFICER
Address: C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD
Signature: /s/ Jonathan Allan, Attorney-in-Fact
Signature date: 19 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STOK transaction

Common Stock

Sale

Transaction value: $117,109
Shares: -3,577
Change %: -6.7%
Price: $32.74
Shares after: 50,071
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1, F2

STOK transaction

Common Stock

Sale

Transaction value: $86,342
Shares: -2,587
Change %: -5.2%
Price: $33.38
Shares after: 47,484
Date: 17 Mar 2026
Ownership: Direct
Footnotes: F1, F3

STOK transaction

Common Stock

Sale

Transaction value: $190,831
Shares: -6,100
Change %: -13%
Price: $31.28
Shares after: 41,384
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F4

STOK transaction

Common Stock

Sale

Transaction value: $15,354
Shares: -483
Change %: -1.2%
Price: $31.79
Shares after: 40,901
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1, F5

STOK transaction

Common Stock

Sale

Transaction value: $3,384
Shares: -103
Change %: -0.25%
Price: $32.85
Shares after: 40,798
Date: 18 Mar 2026
Ownership: Direct
Footnotes: F1

STOK transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,365
Change %: +3.3%
Price: $2.19^*
Shares after: 42,163
Date: 19 Mar 2026
Ownership: Direct
Footnotes: F6

STOK transaction

Common Stock

Sale

Transaction value: $43,815
Shares: -1,461
Change %: -3.5%
Price: $29.99
Shares after: 40,702
Date: 19 Mar 2026
Ownership: Direct
Footnotes: F6

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STOK transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -1,365
Change %: -1.6%
Price: $0.000000^*
Shares after: 83,035
Date: 19 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,365
Exercise price: $2.19
Footnotes: F6, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 7 footnotes

Footnote F1

The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.995 to $32.99 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.855 per share, inclusive.

Footnote F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.59 to $31.58 per share, inclusive.

Footnote F5

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.46 per share, inclusive.

Footnote F6

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2025.

Footnote F7

The option is fully vested and exercisable.